(AGENPARL) – SILVER SPRING mar 13 giugno 2023 The ARC Program strives to increase the number of treatments by promoting innovative scientific design, providing a deeper understanding of regulatory policies, and engaging with patients and their advocates, and other rare disease stakeholders.
Fonte/Source: http://www.fda.gov/news-events/fda-voices/accelerating-rare-disease-cures-arc-program-emerges-conduit-empowering-rare-disease-stakeholders